Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986523 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Arm B | EXPERIMENTAL | - |
| Arm C | EXPERIMENTAL | - |
| Arm D | EXPERIMENTAL | - |
| Arm E | EXPERIMENTAL | - |
| Arm F | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986523 | DRUG | Specified dose on specified days |
| Gemcitabine | DRUG | Specified dose on specified days |
| Nab-Paclitaxel | DRUG | Specified dose on specified days |
| Cetuximab | DRUG | Specified dose on specified days |
| Pembrolizumab | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have a histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with a known Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration (mutation or amplification). * Participants must, for Arm D, have a ...
BMS-986523 is an investigational small molecule being studied in adults with advanced solid malignancies. The Phase 1 trial enrolls patients with non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. It is not approved for any indication and remains in clinical development.
BMS-986523 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is the sole sponsor listed for the ongoing Phase 1 study of the compound in advanced solid malignancies.
BMS-986523 is in Phase 1 clinical development. One Phase 1 trial is currently recruiting, and no later-stage trials have been completed. The study is designed to evaluate safety, tolerability, and efficacy in participants with advanced solid malignancies.
BMS-986523 is being evaluated in the recruiting Phase 1 trial NCT07223047, titled a study of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies. The trial plans to enroll 252 participants across the United States, Canada, and Spain.
Yes. The Phase 1 trial NCT07223047 for BMS-986523 is biomarker selected, meaning enrollment is guided by a defined biomarker rather than an unselected patient population. The study enrolls adults 18 years and older of any sex with advanced solid malignancies.
BMS-986523 is being tested both as a single agent and in combination with anti-cancer agents in the Phase 1 trial NCT07223047. The study is controlled but is not randomized and is not double blinded, and it is currently recruiting participants.